<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982277</url>
  </required_header>
  <id_info>
    <org_study_id>ST/224/219</org_study_id>
    <nct_id>NCT03982277</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy</brief_title>
  <acronym>SAEFRIF</acronym>
  <official_title>A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Higher doses of rifampicin has been associated with a faster drop in bacterial load over
      time, and shorter treatment regimens with high dose rifampicin are being proposed.
      Sub-therapeutic rifampicin concentrations are common in TB patients and have been
      demonstrated in several studies carried out among patients with tuberculosis receiving the
      standard dose (10mg/kg) of rifampicin. Insufficient exposure to isoniazid and rifampicin,
      which are the cornerstones of TB treatment, has been associated with drug resistance,
      treatment failure and delayed bacterial clearance from sputum. Evidence has indicated that
      the current dose of rifampicin (10mg/kg) is inadequate for many patients. Several studies
      have suggested that dose escalation (to 20-35mg/kg) is safe, and that higher doses (35mg/kg)
      may accelerate clearance of TB bacteria from the sputum of infected individuals and
      achievement of target concentrations.15,16 However, these studies have almost entirely been
      conducted among HIV negative TB patients, or TB-HIV co-infected patients without severe
      immunosuppression who are not yet receiving antiretroviral therapy (ART). TB-HIV co-infected
      patients on multiple additional drugs, including ART, are at increased risk of drug-drug
      interactions and drug related toxicities, including hepatotoxicity. Increasing the dose of
      rifampicin is a promising approach; however, there is paucity of data on the safety of higher
      doses of rifampicin in HIV infected patients on ART, and almost no information on the enzyme
      induction effect of high dose rifampicin on Efavirenz (EFV) and Dolutegravir (DTG). In this
      study, the investigators will not only evaluate for the enzyme induction effect of 35mg/kg of
      rifampicin on the most widely used first-line antiretrovirals, but will also look at the
      safety of these combinations in a population in which there is still scarce safety data. The
      aim of this study is to determine the safety of higher doses of rifampicin and its effect on
      the pharmacokinetics of efavirenz and dolutegravir in TB-HIV co-infected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will enroll 120 TB-HIV co-infected patients initiating TB treatment.
      Participants will be randomized to either high dose (35mg/kg) or standard dose (10mg/kg)
      rifampicin in addition to either dolutegravir (DTG) or efavirenz (EFV), for those who are
      antiretroviral therapy (ART) naïve. Patients who are already on ART will remain on their
      current ART regimen. The randomization groups (30 participants in each arm) include:Arm One
      A: R35mg/kg Isoniazid/Ethambutol/Pyrazinamide (HEZ) + DTG, Arm One B: R10mg/kg HEZ + DTG
      (Control 1), Arm Two A: R35mg/kg HEZ + EFV, Arm Two B: R10mg/kg HEZ + EFV (Control 2).

      High dose rifampicin will be administered for the first 8 weeks (intensive phase) of TB
      treatment. All other anti-TB drugs will be administered at the standard dose using fixed-dose
      combinations (FDC). All participants will receive standard dose rifampicin during the
      continuation phase (weeks 9 -24). Pharmacokinetic (PK) blood sampling will be performed after
      6 weeks (±2 weeks) of TB treatment. PK sampling will occur pre-dose and at 1, 2, 4 and 8
      hours after observed dose for rifampicin and DTG concentrations and approximately 12-14 hours
      post-dose for EFV (to measure mid-dose interval (MDI) concentration). The EFV MDI and
      rifampicin pre-dose samples will be collected concurrently in the EFV arms. Safety laboratory
      tests including liver and renal function tests will be measured every two weeks or when
      patients present with symptoms suggestive of toxicity. In participants with culture positive
      TB at baseline, sputum cultures will be performed after 8 weeks of anti-TB treatment.

      The investigators will use population pharmacokinetic modelling to determine the rifampicin
      and DTG exposure in each arm. Using these models the investigators will evaluate for
      drug-drug interactions between ART and the standard and high dose of rifampicin.
      Investigators will compare the mid-dose concentrations of EFV and trough concentrations of
      DTG in each intervention and control arm using Wilcoxon rank-sum test. The investigators will
      also compare the proportion of participants with grade 3 or 4 adverse events in each arm
      using the chi-squared test. Investigators will compare the proportion of participants who are
      sputum culture negative after 8 weeks of treatment among those in the high dose and standard
      dose arms using the chi-squared test.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measures of model predicted exposure/pharmacokinetic (PK) parameters</measure>
    <time_frame>6 (+/-2) weeks from ART initiation</time_frame>
    <description>Area under the concentration-time curve over 24 hours (AUC(0-24h)) of DTG, EFV and rifampicin, by rifampicin dose (10 vs. 35 mg/kg rifampicin)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of high dose rifampicin on DTG and EFV</measure>
    <time_frame>6 (+/-2) weeks from ART initiation</time_frame>
    <description>Maximum concentrations (Cmax), trough concentrations) of DTG, EFV and rifampicin, by rifampicin dose (10 vs. 35 mg/kg rifampicin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of high dose rifampicin</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Grade 3 or 4 laboratory or clinical adverse events, according to the National Institutes of Health Division of AIDS toxicity tables (DAIDS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of high dose rifampicin</measure>
    <time_frame>8 weeks after TB treatment initiation</time_frame>
    <description>Negative sputum cultures</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>High dose Rifampin + DTG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose Rifampicin (35mg/kg ) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose Rifampin + DTG</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Dolutegravir based ART regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose Rifampin + EFV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose rifampicin (35mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose Rifampin + EFV</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard dose rifampicin (10mg/kg) and standard doses of Isoniazid + Ethambutol + Pyrazinamide Efavirenz based ART regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin 300 Mg Oral Capsule</intervention_name>
    <description>High dose rifampicin at 35mg/kg</description>
    <arm_group_label>High dose Rifampin + DTG</arm_group_label>
    <arm_group_label>High dose Rifampin + EFV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of a personally signed and dated informed consent document.

          -  Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other study procedures.

          -  Age of ≥18 years

          -  Confirmed HIV-1 infection

          -  Already started on EFV-based or DTG-based ART or planned to start on ART

          -  Diagnosed with tuberculosis and due to initiate rifampicin-containing therapy

        Exclusion Criteria:

          -  Rifampicin resistant TB identified by baseline Xpert Mycobacterium Tuberculous (MTB)/
             Rifampicin (RIF)

          -  Pregnant women or women planning to get pregnant during TB treatment

          -  Women of reproductive age on DTG who decline the use of effective contraception
             methods (in particular: intrauterine device or condoms)

          -  Decompensated liver disease and/or aminotransferases &gt;5x upper limit of normal (ULN)

          -  Glomerular filtration rate &lt; 50 ml/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Sekaggya-Wiltshire, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Sekaggya-Wiltshire, MBChB, PhD</last_name>
    <phone>256312307000</phone>
    <email>csekaggya@idi.co.ug</email>
  </overall_contact>
  <location>
    <facility>
      <name>Infectious Diseases Institute</name>
      <address>
        <city>Kampala</city>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Sekaggya-Wiltshire, MBChB, PhD</last_name>
      <email>csekaggya@idi.co.ug</email>
    </contact>
    <investigator>
      <last_name>Christine Sekaggya-Wiltshire, MBChB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Milstein M, Lecca L, Peloquin C, Mitchison D, Seung K, Pagano M, Coleman D, Osso E, Coit J, Vargas Vasquez DE, Sanchez Garavito E, Calderon R, Contreras C, Davies G, Mitnick CD. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis. 2016 Aug 27;16(1):453. doi: 10.1186/s12879-016-1790-x.</citation>
    <PMID>27567500</PMID>
  </reference>
  <reference>
    <citation>Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald PR. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother. 2007 Aug;51(8):2994-6. Epub 2007 May 21.</citation>
    <PMID>17517849</PMID>
  </reference>
  <reference>
    <citation>Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis. 2000 Sep;4(9):796-806. Review. Erratum in: Int J Tuberc Lung Dis. 2003 Mar;7(3):304..</citation>
    <PMID>10985648</PMID>
  </reference>
  <reference>
    <citation>Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.</citation>
    <PMID>28100438</PMID>
  </reference>
  <reference>
    <citation>Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, Musaazi J, Gutteck U, Denti P, de Kock M, Jetter A, Byakika-Kibwika P, Eberhard N, Matovu J, Joloba M, Muller D, Manabe YC, Kamya MR, Corti N, Kambugu A, Castelnuovo B, Fehr JS. Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. Clin Infect Dis. 2018 Aug 16;67(5):708-716. doi: 10.1093/cid/ciy179.</citation>
    <PMID>29514175</PMID>
  </reference>
  <reference>
    <citation>Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI, Lee CT, Song J, Lee JH. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. Antimicrob Agents Chemother. 2015 Oct 12;60(1):92-8. doi: 10.1128/AAC.00693-15. Print 2016 Jan.</citation>
    <PMID>26459901</PMID>
  </reference>
  <reference>
    <citation>Burhan E, Ruesen C, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, van Crevel R, Aarnoutse R. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2013 Aug;57(8):3614-9. doi: 10.1128/AAC.02468-12. Epub 2013 May 20.</citation>
    <PMID>23689725</PMID>
  </reference>
  <reference>
    <citation>Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, Berning SE, Gerena GT. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother. 1996 Sep;30(9):919-25.</citation>
    <PMID>8876848</PMID>
  </reference>
  <reference>
    <citation>Sekaggya-Wiltshire C, von Braun A, Scherrer AU, Manabe YC, Buzibye A, Muller D, Ledergerber B, Gutteck U, Corti N, Kambugu A, Byakika-Kibwika P, Lamorde M, Castelnuovo B, Fehr J, Kamya MR. Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. J Antimicrob Chemother. 2017 Apr 1;72(4):1172-1177. doi: 10.1093/jac/dkw534.</citation>
    <PMID>28108678</PMID>
  </reference>
  <reference>
    <citation>Sloan D. Pharmacokinetic Variability in TB Therapy: Associations with HIV and Effect on Outcome. Paper presented at: Conference on Retroviruses and Opportunistic Infections2014.</citation>
  </reference>
  <reference>
    <citation>Chang KC, Leung CC, Yew WW, Kam KM, Yip CW, Ma CH, Tam CM, Leung EC, Law WS, Leung WM. Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur J Clin Microbiol Infect Dis. 2008 Jun;27(6):467-72. doi: 10.1007/s10096-007-0454-6. Epub 2008 Jan 24.</citation>
    <PMID>18214560</PMID>
  </reference>
  <reference>
    <citation>van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? Clin Infect Dis. 2011 May;52(9):e194-9. doi: 10.1093/cid/cir184. Review.</citation>
    <PMID>21467012</PMID>
  </reference>
  <reference>
    <citation>Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE; PanACEA Consortium. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015 May 1;191(9):1058-65. doi: 10.1164/rccm.201407-1264OC.</citation>
    <PMID>25654354</PMID>
  </reference>
  <reference>
    <citation>Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00038-17. doi: 10.1128/AAC.00038-17. Print 2017 Aug. Erratum in: Antimicrob Agents Chemother. 2017 Aug 24;61(9):.</citation>
    <PMID>28559269</PMID>
  </reference>
  <reference>
    <citation>Schutz C, Ismail Z, Proxenos CJ, Marais S, Burton R, Kenyon C, Maartens G, Wilkinson RJ, Meintjes G. Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. S Afr Med J. 2012 Mar 2;102(6):506-11.</citation>
    <PMID>22668951</PMID>
  </reference>
  <reference>
    <citation>Satyaraddi A, Velpandian T, Sharma SK, Vishnubhatla S, Sharma A, Sirohiwal A, Makharia GK, Sinha S, Biswas A, Singh S. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. Int J Tuberc Lung Dis. 2014 Feb;18(2):188-95, i-iii. doi: 10.5588/ijtld.13.0128.</citation>
    <PMID>24429311</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High dose rifampicin</keyword>
  <keyword>TB/HIV co-infected persons</keyword>
  <keyword>safety</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual patient data (IPD) will made available to other researchers for further analysis or met-analysis following direct request to the sponsor (Infectious Diseases Institute).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>6 months after publication of study results.</ipd_time_frame>
    <ipd_access_criteria>Direct request shall be made to Infectious Diseases Institute for pooling of data and met-analysis</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

